The urokinase receptor. A cell surface, regulated chemokine

APMIS

Volumn 107, Issue 1, 1999, Pages 96-101

  Blasi, Francesco ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b HSRaffaele   (Italy)

Author keywords

Chemotaxis; Cytoskeleton; G proteins; Tyrosine kinases; Urokinase receptor

Indexed keywords

GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN TYROSINE KINASE; UROKINASE RECEPTOR;

CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONFORMATIONAL TRANSITION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; RECEPTOR AFFINITY; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033066858     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1699-0463.1999.tb01531.x     Document Type: Review

References (56)

1. 1. Danø K., Andreasen PA, Grøndal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139-266.
2. 2. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. The urokinase-sensitive region of the urokinase receptor is responsible for its potent chemotactic activity. EMBO J 1997;16:7279-86.
3. 3. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic chemokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
4. 4. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nature Med 1996:2:1174-8.
5. 5. Rømer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Danø K. Impaired wound healing in mice with a disrupted plasminogen gene. Nature Med 1996;2:287-92.
6. 6. Blasi F. Urokinase and urokinase receptor: A paracrine/ autocrine system regulating cell migration and invasiveness. BioEssays 1993;15:105-11.
7. 7. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990;88:1-19.
8. 8. Cubellis MV, Wun T-C, Blasi F. Receptor-mediated internalization and degradation of urokinase-PAI-1 complex in human U937 cells. EMBO J 1990;9:1079-85.
9. 2 macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-6.
10. 10. Conese M, Nykjær A, Christensen EI, Petersen CM, Cremona O, Pardi R, Andreasen PA, Gliemann J, Blasi F. Alpha-2 macroglobulin receptor-dependent internalization of the urokinase receptor. J Cell Biol 1995;131:1609-22.
11. 11. Nykjær A, Conese M, Christensen EI, Olson D, Cremona O, Gliemann J, Blasi F. Recycling of the urokinase receptor during internalization of the uPA-serpin complexes. EMBO J 1997;16:2610-20.
12. 12. Gyetko, MR, Chen G-H, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. J Clin Invest I996;97:1818-26.
13. 13. Shapiro RL, Duquetle JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild type mice: cellular bleu nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996;56:3597-604.
14. 14. Pedersen TL, Yong K, Pedersen JO, Hansen NE, Danø K, Plesner T. Impaired migration in vitro of neutrophils from patients with paroxysmal nocturnal hemoglobinuria. Brit J Haematol 1996;95:45-51.
15. 15. Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch K-W, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Medicine 1995;1:1035-9.
16. 16. Sier CFM, Stephens R, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N, Blasi F. Full-size, GPI-anchor free urokinase receptor is increased in serum of ovarian cancer patients. Cancer Res 1998;58:1843-9.
17. 17. Blasi F. uPAR-uPA-PAI-1: a key intersection in proteolysis, adhesion and chemotaxis. Immunol Today 1997;18:415-7.
18. 18. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-33.
19. 19. Sato Y, Rifkin D. Autocrine activity of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988;107:1199-205.
20. 20. Sato YR. Rifkin DB. Inhibition of endothelial cell movement by perycites and smooth muscle cells: Activation of a latent transforming growth factor 1-like molecule by plasmin during co-culture. J Cell Biol 1990;109:309-15.
21. 21. Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M. Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 1988;179:385-95.
22. 22. Odekon LE, Sato Y, Rifkin D. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992;150:258-63.
23. 23. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells. J Cell Biol 1994;126:259-70.
24. 24. Pepper MS, Sappino A-P, Stöcklin R, Montesano R, Orci L, Vassalli J-D. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol 1993;122:673-84.
25. 25. Nusrat AR, Chapman HA Jr. An autocrine role for urokinase in phorbol-ester mediated differentiation of myeloid cell lines. J Clin Invest 1991;87:1091-7.
26. 26. Waltz DA, Sailor LZ, Chapman HA Jr. Cytokines induce urokinase-dependent adhesion of human myeloid cell: a regulatory role for plasminogen activator inhibitors. J Clin Invest 1993;91:1541-52.
27. 27. Rao NK, Shi G-P, Chapman HA Jr. Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest 1995;96:465-74.
28. 28. Waltz DA, Chapman HA Jr. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 1994;269:14746-50.
29. 29. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA Jr. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269:32380-8.
30. 30. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA. Regulation of integrin function by the urokinase receptor. Science 1996;273:1551-5.
31. 31. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs the urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-71.
32. 32. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner K.. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996;224:344-53.
33. 33. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Rønne E, Kobzik L, Chapman HA Jr. Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 1996;88:3185-94.
34. 34. Simon DI, Ezratty AM, Francis SA, Rennke H, LoScalzo J. Fibrin(ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/ CD18): a nonplasmin fibrinolytic pathway. Blood 1993;82:2414-22.
35. 35. Bohuslav J, Horejsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H. Urokinase plasminogen activator receptor, beta-2 integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med 1995;181:1381-90.
36. 36. Xue W, Kindzelskii AL, Todd III RF, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 1994;152:4630-40.
37. 37. Springer TtA, Anderson DC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, chemotaxis and migration into inflammatory sites: insights from an experiment in nature. In: Evered D, Nugent J, O'Connor M, editors. Biochemistry of Macrophages (Ciba Foundation Symposium 118). London: Pittman, 1986: 102-26.
38. 38. Gudewicz PW, Bilboa N. Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Comm 1987;147:1176-81.
39. 39. Boyle MDP, Chiodo VA, Lawman MJP, Gee AP, Young M. Urokinase: a chemotactic factor for polymorphonuclear leukocytes in vivo. J Immunol 1987;139:169-74.
40. 40. Odekon LE, Blasi F, Rifkin D. A requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGFb to TGFb. J Cell Physiol 1994;158:396-407.
41. 41. Gyetko MR, Todd III RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994;93:1380-7.
42. 42. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996;15:1572-82.
43. 43. Pöllänen J, Saksela O, Salonen E-M, Andreasen P, Nielsen L, Dano K, Vaheri A. Distinct localization of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J Cell Biol 1987;104:1085-96.
44. 44. Pöllänen J, Hedman K, Nielsen LS, Danø K, Vaheri A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contact sites. J Cell Biol 1988;106:87-95.
45. 45. Estreicher A, Mühlhauser J, Carpentier J-L, Orci L, Vassalli J-D. The receptor for urokinase-type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 1990;111:783-92.
46. 46. Myöhänen HT, Stephens RW, Hedman K, Tapiovaara H, Rønne E, Høyer-Hansen G, Danø K, Vaheri A. Distribution and lateral mobility of the urokinase receptor complex at the cell surface. J Histochem Cytochem 1993;41:1291-301.
47. 47. Høyer-Hansen G, Ploug M, Behrendt N, Rønne E, Danø K. Cell surface acceleration of urokinase-catalyzed receptor cleavage. Eur J Biochem 1997;243:21-6.
48. 48. Huttenlocher A, Ginsberg MH, Horwitz AF. Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity. J Cell Biol 134: 1551-62.
49. 3 binding to vitronectin. Nature 1996;383:441-3.
50. 50. Kjøller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997;232:420-9.
51. 51. Crowley CW, Cohen RL, Lucas BK, Liu G, Shuman MA, Levinson AD. Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5.
52. 52. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-33.
53. 53. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-9.
54. 54. Hearing VJ, Law LW, Corti A, Appella E, Blasi F. Cell surface urokinase modulates the metastatic potential of B16 melanoma cells. Cancer Res 1988;48:1270-8.
55. 55. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of antisense inhibition of urokinase plasminogen activator receptor in human squamous cell carcinoma on malignancy. EMBO J 1994;13:3983-91.
56. 56. Danø K, Behrendt N, Brünner N, Elis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8 (Suppl. 1): 189-203.